Total Payments
$1.4M
2024 Payments
$65,080
Companies
58
Transactions
2,727
Medicare Patients
1,052
Medicare Billing
$149,683
Payment Breakdown by Category
Other$1.1M (77.7%)
Consulting$158,277 (11.2%)
Travel$74,958 (5.3%)
Food & Beverage$49,267 (3.5%)
Research$30,968 (2.2%)
Education$1,073 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 444 | 77.7% |
| Consulting Fee | $158,277 | 47 | 11.2% |
| Travel and Lodging | $74,958 | 413 | 5.3% |
| Food and Beverage | $49,267 | 1,734 | 3.5% |
| Unspecified | $30,968 | 66 | 2.2% |
| Education | $1,073 | 23 | 0.1% |
Payments by Type
General
$1.4M
2,661 transactions
Research
$30,968
66 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $574,694 | 749 | $0 (2024) |
| Biogen, Inc. | $291,430 | 504 | $0 (2024) |
| EMD Serono, Inc. | $150,531 | 255 | $0 (2024) |
| Genentech USA, Inc. | $102,593 | 164 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $78,252 | 145 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $49,799 | 287 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $47,889 | 139 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $22,356 | 72 | $0 (2019) |
| Celgene Corporation | $22,018 | 50 | $0 (2024) |
| Acorda Therapeutics, Inc | $20,289 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,080 | 194 | EMD Serono, Inc. ($30,954) |
| 2023 | $76,931 | 211 | EMD Serono, Inc. ($30,229) |
| 2022 | $132,122 | 311 | Biogen, Inc. ($54,307) |
| 2021 | $126,124 | 281 | GENZYME CORPORATION ($38,221) |
| 2020 | $95,784 | 201 | Biogen, Inc. ($29,360) |
| 2019 | $247,213 | 456 | GENZYME CORPORATION ($109,426) |
| 2018 | $335,576 | 506 | GENZYME CORPORATION ($186,235) |
| 2017 | $334,331 | 567 | GENZYME CORPORATION ($197,358) |
All Payment Transactions
2,727 individual payment records from CMS Open Payments — Page 1 of 110
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Analgesic | ||||||
| 12/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $31.44 | General |
| Category: Rare Disease | ||||||
| 12/10/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $29.97 | General |
| 12/09/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $47.67 | General |
| 12/07/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: Analgesic | ||||||
| 12/04/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,463.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,273.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,273.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| Category: Neuroscience | ||||||
| 12/02/2024 | InSightec,Inc | Exablate (Device) | Food and Beverage | Cash or cash equivalent | $33.33 | General |
| Category: Neurology | ||||||
| 11/27/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.70 | General |
| 11/26/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 11/22/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,550.00 | General |
| Category: Rare Disease | ||||||
| 11/22/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | Genentech, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $30.96 | General |
| Category: Immunology | ||||||
| 11/18/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: Analgesic | ||||||
| 11/14/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: Rare Disease | ||||||
| 11/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.44 | General |
| 11/08/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $162.81 | General |
| Category: Neurology | ||||||
| 11/08/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $7.88 | General |
| Category: Neurology | ||||||
| 11/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $301.54 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $4,541 | 9 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $3,980 | 11 |
| ACP-103-015 | ACADIA Pharmaceuticals Inc | $3,421 | 3 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $3,321 | 9 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $3,240 | 12 |
| Satralizumab Treatment in Adults With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series | F. Hoffmann-La Roche AG | $2,514 | 2 |
| Satralizumab Treatment in Adult Patients With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: A Case Series | F. Hoffmann-La Roche AG | $1,879 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,547 | 2 |
| COMB157GUS12 | Novartis Pharmaceuticals Corporation | $1,477 | 2 |
| An Extension Protocol for Multiple Sclerosis patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $1,107 | 3 |
| CAMMS323 - CARE-MS I, CAMMS324 - CARE-MS II, and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $959.08 | 2 |
| Satralizumab Treatment in Adult Patients With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series | F. Hoffmann-La Roche AG | $914.18 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Sclerosis Patients Who Participated in Gen | GENZYME CORPORATION | $730.91 | 1 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $678.00 | 3 |
| CAMMS324 - CARE-MS II and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $528.25 | 2 |
| Satralizumab Treatment in Adult Patients With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: Case Series | F. Hoffmann-La Roche AG | $87.48 | 1 |
| CAMMS323 - CARE-MS I and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $43.37 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 244 | 321 | $161,766 | $31,520 |
| 2022 | 6 | 265 | 541 | $204,784 | $37,652 |
| 2021 | 7 | 304 | 601 | $203,783 | $48,103 |
| 2020 | 3 | 239 | 372 | $123,345 | $32,408 |
Total Patients
1,052
Total Services
1,835
Medicare Billing
$149,683
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 214 | $86,008 | $17,699 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 93 | 96 | $75,648 | $13,729 | 18.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 11 | $110.00 | $92.40 | 84.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 190 | 308 | $102,872 | $26,700 | 26.0% |
| 70551 | Mri scan of brain without contrast | Office | 2022 | 21 | 21 | $33,558 | $3,272 | 9.7% |
| 70553 | Mri scan of brain before and after contrast | Office | 2022 | 13 | 13 | $32,019 | $3,134 | 9.8% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2022 | 16 | 16 | $25,888 | $2,541 | 9.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $7,007 | $1,825 | 26.0% |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | Office | 2022 | 14 | 172 | $3,440 | $180.40 | 5.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 205 | 332 | $98,348 | $30,591 | 31.1% |
| 70553 | Mri scan of brain before and after contrast | Office | 2021 | 16 | 17 | $28,879 | $4,586 | 15.9% |
| 70551 | Mri scan brain | Office | 2021 | 25 | 25 | $29,139 | $4,187 | 14.4% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Office | 2021 | 12 | 12 | $20,166 | $3,373 | 16.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $9,399 | $2,716 | 28.9% |
| 72141 | Mri scan of upper spinal canal | Office | 2021 | 16 | 16 | $16,368 | $2,443 | 14.9% |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | Office | 2021 | 13 | 182 | $1,484 | $207.39 | 14.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 199 | 331 | $90,694 | $25,505 | 28.1% |
| 70551 | Mri scan brain | Office | 2020 | 21 | 22 | $22,638 | $3,864 | 17.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 19 | 19 | $10,013 | $3,038 | 30.3% |
About Dr. Brian Steingo, MD
Dr. Brian Steingo, MD is a Neurology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417907163.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Steingo, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $65,080 received in 2024. These payments were reported across 2,727 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Steingo has provided services to 1,052 Medicare beneficiaries, totaling 1,835 services with total Medicare billing of $149,683. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Boca Raton, FL
- Active Since 05/12/2006
- Last Updated 03/21/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1417907163
Products in Payments
- AUBAGIO (Drug) $316,175
- LEMTRADA (Drug) $232,497
- OCREVUS (Biological) $103,718
- TYSABRI (Biological) $87,516
- TECFIDERA (Drug) $85,226
- Mavenclad (Drug) $84,821
- VUMERITY (Drug) $67,741
- COPAXONE (Drug) $46,155
- Rebif (Biological) $32,834
- MAVENCLAD (Drug) $29,551
- ZEPOSIA (Drug) $26,980
- ACTHAR (Biological) $22,485
- GILENYA (Drug) $21,860
- AMPYRA (Drug) $20,018
- Ponvory (Drug) $14,252
- MAYZENT (Drug) $13,029
- ULTOMIRIS (Biological) $11,087
- KESIMPTA (Drug) $9,299
- PLEGRIDY (Biological) $7,996
- Enspryng (Biological) $7,580
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Boca Raton
Dr. Stuart Isaacson, Md, MD
Neurology — Payments: $4.9M
Neurology $4.9M
Dr. Brian Costell, M.d, M.D
Neurology — Payments: $638,608
Neurology $638,608
Dr. Patricio Espinosa, Md,Mph, MD,MPH
Neurology — Payments: $215,050
Neurology $215,050
Dr. Richard Isaacson, M.d, M.D
Neurology — Payments: $140,056
Neurology $140,056
Gediminas Gliebus, M.d, M.D
Neurology — Payments: $120,507
Neurology $120,507
Dr. Richard Dewey, Md, MD
Neurology — Payments: $45,477
Neurology $45,477